The presence of anti-transcriptional intermediary factor 1 antibody (anti-TIF1-Ab) is DM specific and confers an even greater risk of cancer development, with the risk of cancer-associated myositis (CAM; cancer occurring within 3 years prior to or following an IIM onset) ranging from 38 to 71% [5–9]. Here, TRIM24 is linked to myositis disease.